All In Biotech

Drug Trial Radar · NCT07187531

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset of Type 1 Diabetes (NOT1D)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

159

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Nov 2027

Study completion Dec 2028

Sponsor

Lead sponsor
SAb Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

Conditions

  • Type 1 Diabetes

Interventions

  • High Dose SAB-142Drug

    High Dose SAB-142

  • Low Dose SAB-142Drug

    Low Dose SAB-142

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: From dose administration through Week 4
  2. Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)Time frame: From dose administration up to Month 12
  3. Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT).Time frame: Baseline and Month 24

Locations

68 sites in 15 countries. Site status is shown where the registry gives one.

  • University of California San Francisco Benioff Children's Hospital

    San Francisco, California · Recruiting

  • San Jose Clinical Trials, LLC

    San Jose, California · Withdrawn

  • University of Colorado - Barbara Davis Center for Diabetes

    Aurora, Colorado · Recruiting

  • University of Florida College of Medicine

    Gainesville, Florida · Recruiting

  • University of Miami - Gables One Tower

    Miami, Florida · Recruiting

  • Children's Healthcare of Atlanta (CHOA) - Center for Advanced Pediatrics

    Atlanta, Georgia · Recruiting

  • IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology

    Indianapolis, Indiana · Recruiting

  • Harvard Medical School - Joslin Diabetes Center and Joslin Clinical (JDS)

    Boston, Massachusetts · Recruiting

  • Children's Mercy Hospital Kansas City - Pediatric Care Clinic

    Kansas City, Missouri · Recruiting

  • University of New Mexico Hospital

    Albuquerque, New Mexico · Recruiting

  • University at Buffalo MD Physicians Group

    Buffalo, New York · Recruiting

  • Asheville Clinical Research

    Asheville, North Carolina · Recruiting

  • N.C. Children's Hospital - Children's Specialty Clinics - Chapel Hill at Carolina Pointe II

    Chapel Hill, North Carolina · Recruiting

  • Sanford Medical Center Fargo

    Fargo, North Dakota · Recruiting

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Children's Medical Centre Dallas

    Dallas, Texas · Recruiting

  • Cook Children's Medical Center

    Fort Worth, Texas · Recruiting

  • Texas Children's Hospital - Clinical Care Center - Pediatric Renal Clinic

    Houston, Texas · Recruiting

  • San Antonio Clinical Trials

    San Antonio, Texas · Recruiting

  • University of Virginia Health System - Pediatric Diabetes Clinic

    Charlottesville, Virginia · Recruiting

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington · Recruiting

  • Mary Bridge Children's Outpatient Center - Tacoma

    Tacoma, Washington · Recruiting

  • Queensland Children's Hospital

    Brisbane, Australia · Recruiting

  • Perth Children's Hospital

    Nedlands, Australia · Recruiting

  • The Royal Children's Hospital Melbourne

    Parkville, Australia · Recruiting

  • The Royal Melbourne Hospital (RMH)

    Parkville, Australia · Recruiting

  • Royal North Shore Hospital (RNSH)

    St Leonards, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Medizinische Universitaet Graz - Klinik fuer Innere Medizin

    Graz, Austria · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Medizinische Universitaet Graz - Universitaetsklinik fuer Kinder und Jugendheilkunde

    Vienna, Austria · Recruiting

  • Medizinische Universitaet Wien - Universitaetsklinik fuer Kinder und Jugendheilkunde

    Vienna, Austria · Recruiting

  • Universitair Ziekenhuis Brussel

    Jette, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Groupe sante CHC - Clinique du MontLegia

    Liège, Belgium · Recruiting

  • Steno Diabetes Center

    Herlev, Denmark · Recruiting

  • Helsingin Yliopistollinen Keskussairaala

    Helsinki, Finland · Recruiting

  • Turun Yliopistollinen Keskussairaala (TYKS)

    Turku, Finland · Recruiting

  • Universite Paris Descartes - Institut Cochin

    Paris, France · Recruiting

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Universitaire Robert-Debre

    Paris, France · Recruiting

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.